Functional MRI (fMRI) in CGRP Induced Migraine

In patients known with migraine without aura a migraine headache or migraine like headache will be induced by infusion of calcitonin gene related peptide (CGRP). The patients will then be stimulated with noxious heat via a thermode placed at the forehead. At the same time the Blood-oxygenation-level-dependent (BOLD) response will be measured via functional magnetic ressonanse imaging (fMRI), to...

Date First Received: August 11, 2006

Last Updated: August 11, 2006

Verified by: Danish Headache Center, August 2006

Clinical Trial Phase: N/A | Start Date: September 2006

Overall Status: Not yet recruiting

Estimated Enrollment: 12

Brief Summary

Official Title: “Functional MRI (fMRI) in Patients With Migraine Without Aura Provoked by”

Condition Keyword(s):

In patients known with migraine without aura a migraine headache or migraine like headache will be induced by infusion of calcitonin gene related peptide (CGRP). The patients will then be stimulated with noxious heat via a thermode placed at the forehead. At the same time the Blood-oxygenation-level-dependent (BOLD) response will be measured via functional magnetic ressonanse imaging (fMRI), to estimate the central-nervous pain response. The regions of interest (ROI) will be thalamic region and medulla oblongata.

Then the patients will be given pain relif in form of injection of sumatriptan and the effect of this will also be registered via measuring the BOLD response at the RIO's previously defined. A 3-Tesla MRI scanner will be used in this trail.

This study will give us key knowledge of the trigeminal pain pathway and the central processing i.e sensitization during a migraine attach.

Study Type: Interventional

Study Design: Treatment, Non-Randomized, Single Blind, Uncontrolled, Single Group Assignment, Safety Study

Intervention(s) in this Clinical Trial

  • Drug: infusion of calcitonin gene related peptide (CGRP)

Outcome Measures for this Clinical Trial

Primary Measures

  • Changes in BOLD respons before and after CGRP infusion.
  • Changes in BOLD respons before and after injection of sumatriptan.

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • Patients know with migraine without aura.
  • no less then 1 migraine attach pr month and no more then 6 attachs per month.
  • weight 50-100 kg.
  • women must be using secure birthcontrol.

Exclusion Criteria:

  • Tension type headache more then 1 day/month.
  • all other prim. og sec. headache types then migraine without aura.
  • Daily use of medication other then birthcontrol pills.
  • Pregnant and lactation women.
  • Headache on the trail day or 5 days previous to the trail day.
  • Contraindications to MRI-scanns.
  • Hypertension or hypotension.
  • known heart or lung condition.
  • mental illness or substance abuse.
  • Other considerable conditions judged by the examinating doctor.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 55 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Sponsor Information

Lead Sponsor: Danish Headache Center

Overall Clinical Trial Officials and Contacts

Messoud Ashina, MD,PH.d Study Chair Danish Headache Center  

Overall Contact: Mohammad Sohail Asghar, MD +4543232161 asgsoh01@glostruphosp.kbhamt.dk

Additional Information

Information obtained from ClinicalTrials.gov on October 10, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00363532

Study ID Number: KA-20060083

ClinicalTrials.gov Identifier: NCT00363532

Health Authority: Denmark: The Danish National Committee on Biomedical Research Ethics

Clinical Trials Authorship and Review

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.